A retrospective cohort study done on patients' diagnosis with either of RA or psoriasis treated with TNFα inhibitors, methotrexate, HCQ, and other nonbiologic DMARDs reported the reduced relative risk of DM for TNFα inhibitor and HCQ compared with other nonbiologic DMARDs [44]. The gene discussed is TNF; the disease is psoriasis.